Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05524584 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Active, Not Recruiting to Recruiting Primary completion date: Dec 31, 2025 to Dec 31, 2028 · Completion date: Dec 31, 2028 to Dec 31, 2031 · Eligibility criteria expanded, about 26 words · 1 morev7 Show 4 more changesShow less
    • Primary completion date: Dec 31, 2025 to Dec 31, 2028
    • Completion date: Dec 31, 2028 to Dec 31, 2031
    • Eligibility criteria expanded, about 26 words
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Recruiting to Active, Not Recruiting Site details revisedv6 Show 1 more changeShow less
    • Site details revised
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2025v5
  4. Eligibility criteria expanded, about 36 words Secondary endpoints: 6 to 5v4 Show 1 more changeShow less
    • Secondary endpoints: 6 to 5

    See this version in full on ClinicalTrials.gov ↗

  5. Eligibility criteria expanded, about 15 wordsv3 See this version in full on ClinicalTrials.gov ↗
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 2022 to Aug 31, 2022 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Aug 2022 to Aug 31, 2022
    • Site details revised
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast cancer or subjects who have progressed following treatment free interval of more than 12 months following adjuvant or neoadjuvant treatment.
Trial Details
NCT Number NCT05524584
Lead Sponsor University of California, Irvine
Conditions Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov